Earn points on every order New products in stock Free 51-page beginner’s guide
← Back to Compound Library

Selank

Russian anti-anxiety peptide. Calms you down without making you drowsy.

Research referenceCommunity compiled

Molecular profile

The molecule itself: sequence, composition, mass, target, and registry identifiers.

Amino acid sequence

TKPRPGP
7 residues
Molecular formula
C₃₃H₅₇N₁₁O₉
Average mass
751.9 Da
CAS number
129954-34-3
Registry
PubChem CID 11765600
Receptor / pathway
GABA-Amodulation
Formula, mass and identifiers from PubChem CID 11765600. Mass recomputed from the sequence.
Research & reference information

This profile compiles research and community-sourced reference information for educational purposes. Information may evolve as research and community knowledge develop. It is not individualized medical advice.

Overview

Selank is a synthetic heptapeptide derived from the endogenous immunopeptide tuftsin, developed as an allosteric modulator of GABA and a potent anxiolytic.

What problem it targets: It targets generalized anxiety disorder (GAD), chronic psychological stress, mental exhaustion, social unease, and cognitive sluggishness.

What It Does

• Relieves anxiety without sedation: Modulates GABAergic neurotransmission to melt away anxiety and panic without causing muscle weakness, drowsiness, or brain fog.

• Upregulates BDNF and memory function: Stimulates Brain-Derived Neurotrophic Factor in the hippocampus, enhancing learning, focus, and emotional resilience under stress.

• Balances monoamine neurotransmitters: Regulates serotonin, dopamine, and norepinephrine metabolism, producing a calm, clear-headed state of flow.

• Realistic expectations: Does not cause physical dependence, tolerance, or withdrawal like benzodiazepines. Delivered subcutaneously; reduces stress within 15 to 30 minutes while cognitive benefits build over weeks.

Reconstitution

Vial sizeBAC water / SolventConcentration
5 mg+ 1 mL5 mg/mL
10 mg+ 2 mL5 mg/mL

Protocol

PhaseFrequencyDoseUnits (2.5 mg/mL)Units (3.33 mg/mL)Notes
IntranasalDaily AM250–500 mcg2.5–5 sprays2.5–5 spraysDissolve and spray.
SubQDaily AM250–500 mcg10–20u7.5–15.0uSystemic alternative.
Off2 weeks–––Prevents tolerance. Cycle: 4–6 weeks on, 2 weeks off. Timing: Daily SubQ, anytime; calmer than Semax. See Selank (Intranasal) for the nasal-route page. Evidence: Russian-approved (anxiety); no completed Western clinical trials. By sex: Unisex anxiolytic nootropic, no meaningful sex or cycle effect; same protocol for men and women. Avoid in pregnancy.

Handling & Stacking

Injection site
Intranasal (primary). SubQ abdomen (alternative).
Storage
Freeze-dried or solution: refrigerate. Best used within ~6–8 weeks (structure-based estimate); a robust proline-rich peptide, so 28 days is conservative.
Side effects
Mild sedation or relaxation. Rarely: headache. Generally very well tolerated.
What to expect
  • Anxiolytic effect within 20–30 min of intranasal.
  • Clear-headed calmness, not sedating.
  • Memory and focus improvement over 2–4 weeks.
  • No addiction or withdrawal.
  • Supply math 5mg → 3 vials | 10mg → 2 vials (4-wk @ 500 mcg × 7/wk)
Pairs well with
Semax (synergistic nootropic / mood support); BPC-157 (neuroregeneration); GHK-Cu (neuroprotective complement); L-Theanine (calming amplification)
Avoid
MAOIs (theoretical serotonergic interaction). Active psychosis / bipolar mania
Approved drug
  • For anxiety the approved options are SSRIs (sertraline, escitalopram), SNRIs (venlafaxine, duloxetine) and buspirone; all with large trial bases.
  • This peptide has no Western approval or RCT.

Safety & Patient Education

Contraindications
Active psychosis or mania MAOI therapy (theoretical serotonergic interaction) Pregnancy and lactation
Warnings
Approved in Russia / Ukraine / some CIS states, not FDA-approved Quality varies between research-chemical and pharmaceutical-grade suppliers Headache common in initial days (Semax), often responds to choline
Drug interactions
MAOIs: avoid SSRIs/SNRIs: theoretical serotonergic risk, monitor for serotonin syndrome Stimulants: additive activation, reduce dose if combined Sedatives/benzodiazepines: Selank may augment GABA effects
Labs
Compound-specific: CBC + CMP baseline; no compound-specific markers routinely required
Patient education
Neuroactive compounds, effects are real and dosing matters Don’t combine with prescription antidepressants without physician input Russian clinical practice: 10–14 day courses, not continuous
References
researchdosing · peptidedosages · PubMed · thepeptidereport